CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study
10 March 2023. Related: Conference reports, Treatment strategies, Resistance.
Resistance
Low level viral load on effective ART is linked to clonal expansion of reservoir: not affected by modifying ART
1 February 2023. Related: Antiretrovirals, Treatment strategies, Guidelines, Resistance.
Superinfection detected in up to 7% of people in Swiss HIV Cohort Study
1 February 2023. Related: Coinfections and complications, Resistance.
Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence
3 October 2022. Related: Antiretrovirals, Resistance.
Update to IAS-USA drug resistance tables
3 October 2022. Related: Resistance.
Drug resistance profile of integrase inhibitors when treating HIV-2
7 February 2022. Related: Resistance.
Lenacapavir: drug resistance after viral rebound in treatment experienced participants
30 November 2021. Related: Conference reports, Antiretrovirals, Resistance.
Implications of historical M184V on use of dual dolutegravir/lamivudine ART
30 November 2021. Related: Conference reports, Antiretrovirals, Resistance.
UK study for people with triple-class drug resistance
24 February 2021. Related: Resistance, Research studies.
Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study
22 January 2021. Related: Treatment strategies, Resistance.
High rates of drug resistance and virological failure among adults with HIV admitted to hospital in Malawi
9 December 2020. Related: Resistance.
IAS–USA update of drug resistance mutations (2019)
17 July 2019. Related: Guidelines, Resistance.
27th International Workshop on HIV Drug Resistance and Treatment Strategies
20 February 2019. Related: Conference reports, Resistance.
Drug resistance in low- and middle-income countries
20 February 2019. Related: Conference reports, Resistance.
M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy
16 April 2018. Related: Conference reports, Treatment strategies, Resistance.
Bictegravir at CROI 2018: switching studies and drug resistance analyses
14 March 2018. Related: Conference reports, Antiretrovirals, Resistance.
Early ART is not associated with a higher risk of HIV drug resistance
5 January 2018. Related: Treatment strategies, Resistance.
Publications launched at IAS 2017
10 August 2017. Related: Conference reports, Resistance, Other news.
Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence
24 April 2017. Related: Conference reports, Antiretrovirals, Resistance.
No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial
1 August 2016. Related: Conference reports, Paediatric care, Resistance.
Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy
1 December 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, Resistance.
No transmission of integrase-resistant HIV seen in California cohort
1 October 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Resistance.
Transmitted drug resistance in HIV positive pregnant women
1 June 2015. Related: Conference reports, Pregnancy, Resistance.
XXIV International HIV Drug Resistance Workshop , 21-22 February 2015, Seattle, Washington
24 March 2015. Related: Conference reports, Resistance.
Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions
24 March 2015. Related: Conference reports, Resistance.
Higher rates of K65R in non-B subtype in large UK cohort and implications of tenofovir resistance in resource-limited settings
24 March 2015. Related: Conference reports, Resistance.
Drug resistance and integrase inhibitors: potential impact of HIV subtype
24 March 2015. Related: Conference reports, Resistance.
Drug resistance in children after PMTCT and early treatment
24 March 2015. Related: Conference reports, Pregnancy, Paediatric care, Resistance.
Genotyping using dried blood spots in rural South African setting
1 August 2014. Related: Conference reports, Resistance.
NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs
24 March 2014. Related: Conference reports, Treatment strategies, Resistance.
Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive
1 October 2013. Related: HIV prevention and transmission, Resistance.
Dolutegravir update: treatment-naive and -experienced patients and drug resistance
25 July 2013. Related: Conference reports, Antiretrovirals, Resistance.
Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro
25 July 2013. Related: Conference reports, Antiretrovirals, Resistance.
Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance
25 July 2013. Related: Conference reports, Antiretrovirals, Resistance.
S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir
25 July 2013. Related: Conference reports, Antiretrovirals, Resistance.
ddI resistance in South African children failing an abacavir or d4T based first-line regimen
1 April 2013. Related: Conference reports, Antiretrovirals, Paediatric care, Resistance.
US label changes for rilpivirine and Eviplera follows EU caution on high baseline viral load: new summary on drug resistance
1 February 2013. Related: Antiretrovirals, Resistance.
In vitro resistance profile for BMS 986001
1 August 2012. Related: Conference reports, Resistance.
Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B
1 August 2012. Related: Conference reports, Resistance.
Defective viral reservoir populations is common in patients on long-term suppressed ART
1 August 2012. Related: Conference reports, Resistance.
First case report of transmission with five-class resistance
1 August 2012. Related: Conference reports, Resistance.
New data on the Berlin patient: interpret with caution
1 August 2012. Related: Conference reports, Basic science and immunology, Resistance.
Free online resource for treatment decisions without access to genotype resistance tests
1 August 2011. Related: Conference reports, Resistance.
Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy
1 December 2010. Related: Conference reports, Pregnancy, Resistance.
Novel mutations and shifting susceptibility to darunavir and tipranavir
1 October 2010. Related: Conference reports, Antiretrovirals, Resistance.
Darunavir-associated mutations in PI-naive and PI-experienced children in the UK
1 June 2010. Related: Conference reports, Paediatric care, Resistance.
Rate of accumulation of TAMS slow in patients continuing on failing AZT or d4T containing regimens
30 December 2009. Related: Resistance.
Transmitted multidrug-resistant HIV persists in PBMC DNA for years
22 August 2009. Related: Conference reports, Resistance.
Low-level Q148R in people without integrase inhibitor experience
22 August 2009. Related: Conference reports, Resistance.
Cut-offs suggested for predicting efavirenz failure with low-level K103N
22 August 2009. Related: Conference reports, Resistance.
Lower M184V rates with FTC/TDF than with 3TC/TDF
22 August 2009. Related: Conference reports, Resistance.
HBV resistance to lamivudine at undetectable and low levels of viremia
22 August 2009. Related: Conference reports, Hepatitis coinfection, Resistance.
Integrase inhibitor resistance and cross-resistance: weighing viral fitness and the option to benefit from second-generation compounds
30 August 2008. Related: Conference reports, Resistance.
Understanding etravirine susceptibility: new weighted genotype score and phenotypic cut-offs
30 August 2008. Related: Conference reports, Resistance.
Lack of virological impact of treatment intensification in suppressed patients supports latent viral reservoir as source of residual viraemia
30 August 2008. Related: Conference reports, Resistance.
NNRTI resistance in infants prophylaxed with single-dose nevirapine varies by the timing of infection
30 August 2008. Related: Conference reports, Resistance.
Detecting viral tropism: impact of a more sensitive Trofile (ES) assay
30 August 2008. Related: Conference reports, Resistance.
Low frequency K103N mutations are associated with poor virological response to NNRTI based therapy
30 August 2008. Related: Conference reports, Resistance.
Background drugs and low maraviroc levels explain resistance in Motivate studies
1 February 2008. Related: Conference reports, Resistance.
Dual-class mutations affection RTI and NNRTI may be common in experienced patients
1 February 2008. Related: Resistance.
Integrase inhibitors and resistance
7 July 2007. Related: Conference reports, Resistance.
Treatment failure and tropism changes in maraviroc trial related to previously undetected CXCR4, rather than a mutational shift from CCR5
3 July 2007. Related: Conference reports, Resistance.
Mechanisms of failure to CCR5 inhibitors is not explained by mutation in the V3 loop, cross-resistance between CCR5 inhibitors is likely
3 July 2007. Related: Conference reports, Resistance.
Higher risk of resistance using lopinavir/r monotherapy
3 July 2007. Related: Conference reports, Resistance.
Macaque study shows similar protection from rectal exposure using 2-hour pre- and 24-hour post exposure prophylaxis with tenofovir plus FTC compared to daily regimen
3 July 2007. Related: Conference reports, Resistance.